Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,417.64
(
-0.92%
)
US TECH 100
22,718.00
(
-1.02%
)
Dow Jones
45,548.34
(
-0.90%
)
Brent Oil
104.04
(
3.34%
)
Bitcoin
65,803.00
(
-4.34%
)
News Focus
News Focus
Post# of 257295
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122815
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jbog post# 237913

Friday, 04/30/2021 8:41:19 AM

Friday, April 30, 2021 8:41:19 AM

Post# of 257295
ABBV 1Q21 Mavyret sales=$415M, -14% QoQ:

https://news.abbvie.com/news/press-releases/abbvie-reports-first-quarter-2021-financial-results.htm

The $415M consisted of: $170M US (-23% QoQ); and $245M ex-US (-6%, QoQ).

ABBV’s prior guidance for full-year 2021 Mavyret sales is $2.0B (#msg-161451655). This figure could still be met if patient starts (especially in the US) pick up due to lessening of COVID; however, ABBV may lower the guidance during today’s CC.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today